Viral Genetics, Inc. (PINK:VRAL), a development-stage biotechnology company, is promoted again. Additionally, the company posted a President’s Letter to Shareholders.
The market performance of VRAL hasn’t been all that convincing since the beginning of 2012. Yesterday, VRAL closed up 7.91% at $0.015 with approximately 1.46 million shares changing hands. This is about 25% down year to date.[BANNER]
In the hopes to turn things around, or dump some shares, an undisclosed third party paid $2.5 thousand for a promotion.
The letter to VRAL shareholders published earlier today, may also have an effect on the market. It suggests it is possible that VRAL will start generating revenue “as soon as later this year.” A very positive suggestion, albeit vague.
Generating revenue would be a welcome change for shareholders who have had to endure net losses of almost $80 million since the company’s inception in 1995. Other than optimistic expectations and plans coming from the company itself, VRAL doesn’t have much going its way for now.
